Blueprint Medicines Corp expected to post a loss of $2.67 a share - Earnings Preview

Blueprint Medicines

02/05/2023 19:40

* Blueprint Medicines Corp  BPMC.OQ   BPMC.O  is expected
to show
a fall in quarterly revenue when it reports  results on May 4. 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 33.1% decrease in revenue to $41.956 million from $62.73
million a year ago, according to the mean estimate from 16
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Blueprint Medicines
Corp
is for a loss of $2.67 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 6
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 0.1%
in the last three months. ​
    * Wall Street's median 12-month price target for Blueprint
Medicines Corp is $70​, above​ its last closing price of $51.50.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -2.65       -2.65      -2.65     Met     0
 Sep. 30 2022  -2.46       -2.49      -2.23     Beat    10.3
 Jun. 30 2022  -2.25       -2.23      -2.68     Missed  -20.3​
 Mar. 31 2022  -1.78       -1.86      -1.79     Beat    3.9
 ​​Dec.        -2.48       -1.65      -5.40     Missed  -228.1
 31 2021                                                
 Sep. 30 2021  -1.63       -1.63      -1.94     Missed  -19.1​
 Jun. 30 2021  -1.83       -1.86      -1.86     Met     0
 Mar. 31 2021  -1.91       -1.87      -1.72     Beat    8
 This summary was machine generated May 2 at 18:40 GMT.  All
figures in US dollars  unless otherwise stated